Question normal

1) Why was the dose of 0.2 mcg/kg of background vasopressors considered high dose when in clinical practice initial dose can be as high as 10-12 mcg/kg of Levophed and maintenance dose of upto 4 mcg/kg

2) Why was the study not powered to statistically detect mortality benefit as other vasopressors also raise MAP but not necesarrily have mortality benefit? What makes Ag II any different?

3) Where does the Ag II drug stand currently with FDA approval?